“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

Moderna said that the result – which showed its shot was around 26.6% more effective than the comparator – sets up regulatory filings both for mRNA-1010 and its combination flu and COVID-19 ...

Short sellers started to panic in recent days. Moderna (MRNA), which has a short interest of 16.44%, might benefit from two ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

According to the CDC, there has been a decline in animal infections and no reports of human cases since February.

Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

The U.S. Centers for Disease Control and Prevention has merged H5N1 bird flu updates with routine updates for seasonal ...

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...

Alkaline. Electrolyte. Flavored. Walk down the beverage aisle and you'll find all kinds of waters promising extra health ...